Comparison window: — · currency: 🇪🇺 EUR · inflation: 🇮🇹 Italy · distributions: reinvested where declared
Informational document generated by rebalix.com — facts side by side, no recommendations. It does not constitute investment advice or investment research under Directive 2014/65/EU (MiFID II). Past performance is not indicative of future results.
| Metric | 500E | AQUIL | Note |
|---|---|---|---|
| Identity | |||
| Category | Equity · United States · Large cap | Equity · United States · Large cap | Rebalix engine classification |
| Replication | Synthetic (swap) | Physical | as declared by the issuer |
| Currency hedging | No | No | source: class name, factsheet |
| Income policy | accumulating | accumulating | — |
| Costs | |||
| TER | 0.15% | 0.10% | from the KID |
| Transaction costs (KID) | 0.00% | 0.00% | internal |
| All-in cost | 0.15% | 0.10% | TER + transaction |
| Tracking difference (3a) | +0.29% | — | vs its OWN index |
| Performance in euro (ECB rates) | |||
| 1 year | +22.3% | — | — |
| 3 years | +65.7% | — | — |
| 5 years | +85.4% | — | — |
| 10 years | — | — | — = series younger than the window |
| Risk · last 3 years | |||
| Volatility (ann.) | +14.81% | — | — |
| Max drawdown | −18.77% | — | — |
| Sharpe | 1.14 | — | risk-free = ECB MRO avg |
| Sortino | 1.67 | — | like Sharpe, downside only |
| Italian taxation | |||
| Effective capital-gains rate | 26.00% | 26.00% | white list, current half-year |
| Documents & exchanges | |||
| Listing venues | 7 | 1 | ESMA register |
| Borsa Italiana ticker | — | AQUIL | — |
This document is for information only and does not constitute investment advice under Directive 2014/65/EU (MiFID II), investment research, a personal recommendation, or an offer or solicitation to buy or sell financial instruments.
Past performance is not indicative of, nor a guarantee of, future results. The value of an investment can go down as well as up and investors may not get back the capital invested. Euro returns are affected by currency fluctuations.
Before any investment decision, read the KID and the Prospectus, available from the issuers. Tax treatment depends on individual circumstances and may change.
Data come from official issuer documents and public registers, following the public methodology at rebalix.com/en/methodology. "—" fields were not published by the source and have not been estimated. Rebalix receives no compensation from the issuers mentioned.